BJU International

Papers
(The H4-Index of BJU International is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Sexual function in adolescence after childhood hypospadias repair: a patient‐reported outcome study91
Reply to ‘Comment on Bertini et al.: area deprivation and PSA screening disparities’ and ‘Comment on socioeconomic disparities in prostate cancer screening: the impact of the Area Deprivati80
NeuroSAFE in radical prostatectomy increases the rate of nerve‐sparing surgery without affecting oncological outcome64
Impact of the COVID‐19 pandemic on the burnout rates of graduating Canadian Urology residents58
Risk factors and natural history of parastomal hernia after radical cystectomy and ileal conduit51
Building a research profile during residency51
Response to Chen et al.51
The European Association of Urology talent incubator: bridging competencies for holistic urological care46
Surveillance of non‐muscle ‐invasive bladder cancer with blue‐light cystoscopy: a meta‐analysis45
April's reviewers of the month45
Acupuncture: a promising adjuvant strategy for pain management among the patients with prostate cancer44
42
April's reviewers of the month42
Prolonged ischaemia during partial nephrectomy: impact of warm vs cold40
Efficacy of RestoreX after prostatectomy: open‐label phase of a randomised controlled trial40
Aligning germline and somatic mutations in prostate cancer. Are genetics changing practice?39
Nephrectomy for kidney tumour increases the risk of de novo arterial hypertension37
Comparison of the effects of extrinsic compression on the drainage performance of three ureteric stents36
Recent key papers in prostate cancer35
Vitamin C as an adjunct to methenamine hippurate use after ALTAR: ego or evidence‐based?33
The LANDMARK project: providing summaries of key papers that have shaped urological practice32
Real‐world performance of Uromonitor® in urothelial bladder cancer detection: a multicentric trial31
Active surveillance versus enzalutamide for low‐risk prostate cancer – was it really a trial we needed?31
Editorial Board31
Author Index29
Flexible ureterorenoscopy or extracorporeal shockwave lithotripsy in stone disease and bevacizumab for hereditary and sporadic papillary renal‐cell cancer29
29
Comment on: ‘Residents surgical training using metrics for transurethral resection of bladder tumours’28
0.24421000480652